Spectroscopic Ellipsometry Detection of Prostate Cancer Bio-Marker PCA3 Using Specific Non-Labeled Aptamer: Comparison with Electrochemical Detection †
Abstract
:1. Introduction
2. Materials and Methods
2.1. Chemicals
2.2. TIRE-Optical Bio-Transducer
3. Results and Discussion
3.1. Results of TIRE Single Spectroscopic Measurements
3.2. TIRE Study of the Binding Kinetics
4. Conclusions: Comparison of the Electrochemical and Optical Detection Strategies
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef]
- Liss, M.A.; Santos, R.; Osann, K.; Lau, A.; Ahlering, T.E.; Ornstein, D.K. PCA3 molecular urine assay for prostate cancer: Association with pathologic features and impact of collection protocols. World J. Urol. 2011, 29, 683–688. [Google Scholar] [CrossRef] [Green Version]
- Daniyal, M.; Siddiqui, Z.A.; Akram, M.; Asif, H.M. MINI-REVIEW Epidemiology, Etiology, Diagnosis and Treatment of Prostate Cancer. Asian Pac. J. Cancer Prev. 2014, 15, 9575–9578. [Google Scholar] [CrossRef] [Green Version]
- Filella, X.; Foj, L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Int. J. Mol. Sci. 2016, 17, 1784. [Google Scholar] [CrossRef]
- Miller, K.D.; Siegel, R.L.; Lin, C.C.; Mariotto, A.B.; Kramer, J.L.; Rowland, J.H.; Stein, K.D.; Alteri, R.; Jemal, A. Cancer treatment and survivorship statistics, 2016. CA A Cancer J. Clin. 2016, 66, 271–289. [Google Scholar] [CrossRef] [Green Version]
- Salman, J.W.; Schoots, I.G.; Carlsson, S.; Jenster, G.; Roobol, M.J. Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. In Advances in Experimental Medicine and Biology; Springer: Dordrecht, The Netherlands, 2015; Volume 867, pp. 93–114. [Google Scholar] [CrossRef]
- Buzzoni, C.; Auvinen, A.; Roobol, M.J.; Carlsson, S.; Moss, S.M.; Puliti, D.; de Koning, H.J.; Bangma, C.H.; Denis, L.J.; Kwiatkowski, M.; et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur. Urol. 2015, 68, 885–890. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adhyam, M.; Gupta, A.K. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J. Surg. Oncol. 2012, 3, 120–129. [Google Scholar] [CrossRef] [Green Version]
- Mistry, K.; Cable, G. Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma. J. Am. Board Fam. Med. 2003, 16, 95–101. [Google Scholar] [CrossRef] [Green Version]
- Altuwaijri, S. Role of Prostate Specific Antigen (PSA) in Pathogenesis of Prostate Cancer. J. Cancer Ther. 2012, 3, 331–336. [Google Scholar] [CrossRef] [Green Version]
- Landers, K.A.; Burger, M.J.; Tebay, M.A.; Purdie, D.M.; Scells, B.; Samaratunga, H.; Lavin, M.F.; Gardiner, R.A. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int. J. Cancer 2005, 114, 950–956. [Google Scholar] [CrossRef]
- Bussemakers, M.J.; Van Bokhoven, A.; Verhaegh, G.W.; Smit, F.P.; Karthaus, H.F.; Schalken, J.A.; Debruyne, F.M.; Ru, N.; Isaacs, W.B. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59, 5975–5979. [Google Scholar]
- Chistiakov, D.A.; Myasoedova, V.A.; Grechko, A.V.; Melnichenko, A.A.; Orekhov, A.N. New biomarkers for diagnosis and prognosis of localized prostate cancer. Semin. Cancer Biol. 2018, 52, 9–16. [Google Scholar] [CrossRef] [PubMed]
- Rönnau, C.G.H.; Verhaegh, G.W.; Luna-Velez, M.V.; Schalken, J.A. Noncoding RNAs as Novel Biomarkers in Prostate Cancer. BioMed Res. Int. 2014, 2014, 591703. [Google Scholar] [CrossRef]
- Schalken, J.A.; Hessels, D.; Verhaegh, G. New targets for therapy in prostate cancer: Differential display code 3 (DD3PCA3), a highly prostate cancer–specific gene. Urology 2003, 62, 34–43. [Google Scholar] [CrossRef]
- Nicholson, A.; Mahon, J.; Boland, A.; Beale, S.; Dwan, K.; Fleeman, N.; Hockenhull, J.; Dundar, Y. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: A systematic review and economic evaluation. Health Technol. Assess. 2015, 19, 1–192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pasinszki, T.; Krebsz, M.; Tung, T.T.; Losic, D. Carbon Nanomaterial Based Biosensors for Non-Invasive Detection of Cancer and Disease Biomarkers for Clinical Diagnosis. Sensors 2017, 17, 1919. [Google Scholar] [CrossRef] [Green Version]
- Topkaya, S.N.; Azimzadeh, M.; Ozsoz, M. Electrochemical Biosensors for Cancer Biomarkers Detection: Recent Advances and Challenges. Electroanalysis 2016, 28, 1402–1419. [Google Scholar] [CrossRef]
- Marangoni, K.; Neves, A.F.; Rocha, R.M.; Faria, P.R.; Alves, P.T.; Souza, A.G.; Fujimura, P.T.; Santos, F.A.A.; Araújo, T.G.; Ward, L.S.; et al. Prostate-specific RNA aptamer: Promising nucleic acid antibody-like cancer detection. Sci. Rep. 2015, 5, 12090. [Google Scholar] [CrossRef] [Green Version]
- Nabok, A.; Abu-Ali, H.; Takita, S.; Smith, D. Electrochemical Detection of Prostate Cancer Biomarker PCA3 Using Specific RNA-Based Aptamer Labelled with Ferrocene. Chemosensors 2021, 9, 59. [Google Scholar] [CrossRef]
- Arwin, H.; Poksinski, M.; Johansen, K. Total internal reflection ellipsometry: Principles and applications. Appl. Opt. 2004, 43, 3028–3036. [Google Scholar] [CrossRef] [PubMed]
- Nabok, A.; Tsargorodskaya, A.; Mustafa, M.; Szekacs, I.; Starodub, N.; Szekacs, A. Detection of low molecular weight toxins using an optical phase method of ellipsometry. Sens. Actuators B Chem. 2011, 154, 232–237. [Google Scholar] [CrossRef]
- Al Rubaye, A.; Nabok, A.; Catanante, G.; Marty, J.-L.; Takacs, E.; Szekacs, A. Detection of ochratoxin A in aptamer assay using total internal reflection ellipsometry. Sens. Actuators B Chem. 2018, 263, 248–251. [Google Scholar] [CrossRef] [Green Version]
- Al-Rubaye, A.G.; Nabok, A.; Catanante, G.; Marty, J.-L.; Takács, E.; Székács, A. Label-Free Optical Detection of Mycotoxins Using Specific Aptamers Immobilized on Gold Nanostructures. Toxins 2018, 10, 291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Takita, S.; Nabok, A.; Smith, D.; Lishchuk, A. Spectroscopic Ellipsometry Detection of Prostate Cancer Bio-Marker PCA3 Using Specific Non-Labeled Aptamer: Comparison with Electrochemical Detection. Chem. Proc. 2021, 5, 65. https://doi.org/10.3390/CSAC2021-10453
Takita S, Nabok A, Smith D, Lishchuk A. Spectroscopic Ellipsometry Detection of Prostate Cancer Bio-Marker PCA3 Using Specific Non-Labeled Aptamer: Comparison with Electrochemical Detection. Chemistry Proceedings. 2021; 5(1):65. https://doi.org/10.3390/CSAC2021-10453
Chicago/Turabian StyleTakita, Sarra, Alexei Nabok, David Smith, and Anna Lishchuk. 2021. "Spectroscopic Ellipsometry Detection of Prostate Cancer Bio-Marker PCA3 Using Specific Non-Labeled Aptamer: Comparison with Electrochemical Detection" Chemistry Proceedings 5, no. 1: 65. https://doi.org/10.3390/CSAC2021-10453
APA StyleTakita, S., Nabok, A., Smith, D., & Lishchuk, A. (2021). Spectroscopic Ellipsometry Detection of Prostate Cancer Bio-Marker PCA3 Using Specific Non-Labeled Aptamer: Comparison with Electrochemical Detection. Chemistry Proceedings, 5(1), 65. https://doi.org/10.3390/CSAC2021-10453